FDA Reaffirms Safety And Efficacy Of Rivaroxaban

–FDA says no changes needed to the rivaroxaban label. Following a year of controversy and uncertainty relating to the anticoagulant drug rivaroxaban (Xarelto, Johnson & Johnson), the FDA has reaffirmed the drug’s safety and efficacy. Rivaroxaban is approved for stroke reduction in patients with atrial fibrillation. The indication is based on results of the ROCKET-AF...Click here to continue reading...

Source: CardioBrief - October 11, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms People, Places & Events Policy & Ethics FDA rivaroxaban ROCKET warfarin Xarelto Source Type: blogs